MedPath

SURPASS Retrospective Study

Completed
Conditions
Breast MRI
Sentinel Lymph Node
Breast Cancer
Neoadjuvant Systemic Therapy
Registration Number
NCT05779982
Lead Sponsor
Gangnam Severance Hospital
Brief Summary

This study aimed to determine whether sentinel lymph node biopsy (SLNB) could be a reliable option for evaluating nodal status in patients who had responded well to neoadjuvant systemic therapy (NAST), even if they had initially presented with a high nodal burden. The study investigated the outcomes of SLNB followed by axillary lymph node dissection (ALND) in this patient population, taking into account the response to NAST and the breast cancer subtype.

Detailed Description

To determine the feasibility of sentinel lymph node biopsy (SLNB) in this study, the investigators evaluated the false-negative rate (FNR) of SLNB. The FNR was calculated as the number of patients with negative SLNs who had a residual disease in the rest of the axillary lymph nodes (ALNs) divided by the total number of patients with residual disease in either the SLNs, the rest of the ALNs, or both: FN/true-positive + FN. The investigators compared the FNR of the SLNB according to the radiologic response measured using breast MRI in each subtype. The investigators further evaluated the FNR in subgroups stratified by clinical nodal stage. Additionally, the investigators assessed additional metastatic ALNs in cases with 1-2 metastatic SLNs through the completion of ALN dissection.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
500
Inclusion Criteria
  • cN1-3 breast cancer at initial presentation
  • received neoadjuvant systemic therapy (NAST)
  • received sentinel lymph node biopsy (SLNB) followed by additional axillary lymph node dissection (ALND)
  • breast MRI performed at baseline and post-NAST.
Exclusion Criteria
  • case with unavailable data for breast MRI and operation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
False negative rate of sentinel lymph node biopsy according to radiologic response stratified by brest cancer subtypeup to 1 month after the breast surgery

False negative rate of sentinel lymph node biopsy according to radiologic response stratified by brest cancer subtype

Secondary Outcome Measures
NameTimeMethod
False negative rate of sentinel lymph node biopsy according to clinical nodal stageup to 1 month after the breast surgery

False negative rate of sentinel lymph node biopsy according to clinical nodal stage

Additional axillary lymph node metastasis rate in patients with 1-2 metastatic sentinel lymph nodesup to 1 month after the breast surgery

Additional axillary lymph node metastasis rate in patients with 1-2 metastatic sentinel lymph nodes

© Copyright 2025. All Rights Reserved by MedPath